NCT07118202View on ClinicalTrials.gov

TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma

NARecruitingINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
Hepatocellular Carcinoma Recurrent
Interventions
DEVICE

TheraBionic P1

Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three 60-minute treatments per day, administered in the morning, middle of the day, and in the evening

Trial Locations (1)

48201

RECRUITING

Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

THERABIONIC INC.

OTHER

lead

Barbara Ann Karmanos Cancer Institute

OTHER